Pharmacyclics Announces Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) at the European ...
13:50 EDT 16 Jun 2012 | LaMerie
Investigational agent ibrutinib demonstrates prolonged progression-free survival (PFS)
Original Article: Pharmacyclics Announces Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) at the European ...
More From BioPortfolio on "Pharmacyclics Announces Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) at the European ..."
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
